Fuller Andrew P, Palmer-Toy Darryl, Erlander Mark G, Sgroi Dennis C
Department of Pathology, Harvard Medical School, Molecular Pathology Research Unit, Massachusetts General Hospital, Boston, Massachusetts, USA.
J Mammary Gland Biol Neoplasia. 2003 Jul;8(3):335-45. doi: 10.1023/b:jomg.0000010033.49464.0c.
Advances in comprehensive genomic and proteomic technologies are providing researchers with an unprecedented opportunity for high-throughput molecular analysis of human breast cancer. Adaptation of these technologies to laser capture microdissection (LCM) is poised to exert dramatic change on the pace of breast cancer research. Although technical limitations have impeded the coupling of these high-throughput technologies to LCM, recent advances have allowed for the successful application of this cellular-based approach to breast cancer, and the results of such studies have provided researchers with unique insight into the disease. This approach holds great potential for rapid advancement in our understanding of breast cancer, and it is hoped that such advancements will lead to novel predictive and therapeutic strategies for women with the disease. This review outlines the current status of the adaptation of advanced molecular technologies to LCM and highlights recent studies in which this approach has been applied to human breast cancer.
综合基因组学和蛋白质组学技术的进步为研究人员提供了前所未有的机会，可对人类乳腺癌进行高通量分子分析。将这些技术应用于激光捕获显微切割（LCM）有望极大地改变乳腺癌研究的步伐。尽管技术限制阻碍了这些高通量技术与LCM的结合，但最近的进展已使这种基于细胞的方法成功应用于乳腺癌研究，此类研究结果为研究人员提供了对该疾病的独特见解。这种方法在快速推进我们对乳腺癌的理解方面具有巨大潜力，希望这些进展将为患有该疾病的女性带来新的预测和治疗策略。本综述概述了先进分子技术应用于LCM的现状，并重点介绍了最近将该方法应用于人类乳腺癌的研究。
